Home/Filings/4/0000805928-25-000041
4//SEC Filing

DeVinney Erick Wayne 4

Accession 0000805928-25-000041

CIK 0000805928other

Filed

Mar 18, 8:00 PM ET

Accepted

Mar 19, 5:24 PM ET

Size

18.2 KB

Accession

0000805928-25-000041

Insider Transaction Report

Form 4
Period: 2025-03-16
DeVinney Erick Wayne
VP of Clin. & Trans. Sciences
Transactions
  • Exercise/Conversion

    Common Stock

    2025-03-16+6,362209,723 total
  • Exercise/Conversion

    Common Stock

    2025-03-16+23,150232,873 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-03-1623,15023,150 total
    Common Stock (23,150 underlying)
  • Exercise/Conversion

    Common Stock

    2025-03-16+2,950203,361 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-03-162,9500 total
    Common Stock (2,950 underlying)
  • Sale

    Common Stock

    2025-03-19$17.50/sh15,111$264,443217,762 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-03-166,3626,363 total
    Common Stock (6,362 underlying)
Footnotes (7)
  • [F1]This reflects the number of restricted stock units that became vested as of March 16, 2025.
  • [F2]Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units on March 16, 2025. This sale does not represent a discretionary trade by the Reporting Person.
  • [F3]The reported price in Column 4 is a weighted average sale price. These shares were sold on March 19, 2025 in multiple transactions at $17.50 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • [F4]Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
  • [F5]All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date.
  • [F6]All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
  • [F7]All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

Issuer

Axogen, Inc.

CIK 0000805928

Entity typeother

Related Parties

1
  • filerCIK 0001595972

Filing Metadata

Form type
4
Filed
Mar 18, 8:00 PM ET
Accepted
Mar 19, 5:24 PM ET
Size
18.2 KB